Atossa Therapeutics, Inc. SEC filings ATOS
Atossa Therapeutics, Inc. has 641 filings in SEC EDGAR's recent list, going back to Mar 30, 2010. Its latest annual report, Form ARS, was filed on Mar 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 7, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 9, 2026 (material agreement, change to shareholder rights, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | Mar 30, 2026 | Mar 30, 2026 |
| PRE 14A | Preliminary proxy statement | Mar 20, 2026 | Mar 20, 2026 |
| DEF 14A | Proxy statement | Dec 22, 2025 | Dec 19, 2025 |
| PRE 14A | Preliminary proxy statement | Dec 12, 2025 | Dec 12, 2025 |
| DEF 14A | Proxy statement | Mar 26, 2025 | Mar 26, 2025 |
| DEF 14A | Proxy statement | May 23, 2024 | May 23, 2024 |
| PRE 14A | Preliminary proxy statement | May 10, 2024 | May 10, 2024 |
| DEFA14A | Additional proxy material | Apr 26, 2023 | — |
| DEF 14A | Proxy statement | Mar 30, 2023 | May 4, 2023 |
| DEF 14A | Proxy statement | Apr 11, 2022 | May 13, 2022 |
| PRE 14A | Preliminary proxy statement | Apr 1, 2022 | May 13, 2022 |
| DEFA14A | Additional proxy material | Sep 14, 2021 | — |
| DEF 14A | Proxy statement | Aug 9, 2021 | Sep 7, 2021 |
| PRE 14A | Preliminary proxy statement | Jul 29, 2021 | Sep 7, 2021 |
| DEFA14A | Additional proxy material | May 11, 2021 | — |
| DEF 14A | Proxy statement | Apr 15, 2021 | May 14, 2021 |
| PRE 14A | Preliminary proxy statement | Apr 5, 2021 | May 14, 2021 |
| DEF 14A | Proxy statement | Apr 13, 2020 | May 15, 2020 |
| DEF 14A | Proxy statement | Apr 12, 2019 | May 16, 2019 |
| DEFA14A | Additional proxy material | Apr 16, 2018 | — |
| DEFA14A | Additional proxy material | Apr 2, 2018 | — |
| DEF 14A | Proxy statement | Mar 20, 2018 | Apr 12, 2018 |
| PRE 14A | Preliminary proxy statement | Mar 8, 2018 | Mar 8, 2018 |
| DEF 14A | Proxy statement | Apr 13, 2017 | May 9, 2017 |
| DEF 14A | Proxy statement | Apr 13, 2016 | May 18, 2016 |
| PRE 14A | Preliminary proxy statement | Apr 1, 2016 | Apr 1, 2016 |
| DEF 14A | Proxy statement | Apr 15, 2015 | May 11, 2015 |
| DEF 14A | Proxy statement | Apr 11, 2014 | May 5, 2014 |
| DEF 14A | Proxy statement | Apr 15, 2013 | May 6, 2013 |
Showing 29 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ATOS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Seattle, WA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1488039
- Former names
- ATOSSA GENETICS INC (until Nov 13, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.